Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

被引:71
|
作者
Schiffmann, R
Rapkiewicz, A
Abu-Asab, M
Ries, M
Askari, H
Tsokos, M
Quezado, M
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA
关键词
Fabry disease; lysosomes; atherosclerosis; myocardial infarction; enzyme replacement therapy; glycolipids;
D O I
10.1007/s00428-005-0089-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant alpha-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with alpha-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 50 条
  • [21] An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naive to enzyme replacement therapy
    Goker-Alpan, Ozlem
    Longo, Nicola
    McDonald, Marie
    Shankar, Suma P.
    Schiffmann, Raphael
    Chang, Peter
    Shen, Yinghua
    Pano, Arian
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1771 - 1781
  • [22] Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease
    Hirashio, S.
    Taguchi, T.
    Naito, T.
    Maki, K.
    Ogata, S.
    Taniyama, K.
    Taniguchi, Y.
    Yorioka, N.
    CLINICAL NEPHROLOGY, 2009, 71 (05) : 550 - 556
  • [23] Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis
    Muto, Reiko
    Suzuki, Yasuhiro
    Shimizu, Hideaki
    Yasuda, Kaoru
    Ishimoto, Takuji
    Maruyama, Shoichi
    Ito, Yasuhiko
    Mizuno, Masashi
    INTERNAL MEDICINE, 2023, 62 (03) : 565 - 569
  • [24] Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
    David F Moore
    Gheona Altarescu
    Peter Herscovitch
    Raphael Schiffmann
    BMC Neurology, 2
  • [25] Cost-effectiveness of enzyme replacement therapy for Fabry disease
    Saskia M Rombach
    Carla EM Hollak
    Gabor E Linthorst
    Marcel GW Dijkgraaf
    Orphanet Journal of Rare Diseases, 8
  • [26] Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
    Ramaswami, U.
    Wendt, S.
    Pintos-Morell, G.
    Parini, R.
    Whybra, C.
    Leon Leal, J. A.
    Santus, F.
    Beck, M.
    ACTA PAEDIATRICA, 2007, 96 (01) : 122 - 127
  • [27] Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
    Moore, David F.
    Altarescu, Gheona
    Herscovitch, Peter
    Schiffmann, Raphael
    BMC NEUROLOGY, 2002, 2 (1)
  • [28] Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
    Caballero, L.
    Climent, V.
    Hernandez-Romero, D.
    Quintanilla, M. A.
    de la Morena, G.
    Marin, F.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (16) : 1679 - 1689
  • [29] Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort
    Arends, Maarten
    Linthorst, Gabor E.
    Hollak, Carla E.
    Biegstraaten, Marieke
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : 194 - 198
  • [30] Agalsidase alfa for enzyme-replacement therapy in Fabry disease
    Mehta, Atul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (05) : 641 - 652